![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Details:
The collaboration aims at combining Inteligex’s more than twenty years of experience in cell-based therapies and NurExone’s innovative exosome platform to develop therapies for patients with chronic spinal cord injuries.
Lead Product(s): Exosome-based Therapy
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Inteligex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2024